Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents

Journal of Clinical Pharmacology
Sally SelimLaura Rabinovich-Guilatt

Abstract

This multisite open-label study sought to characterize the pharmacokinetics and safety of a single dose of inhaled loxapine in children and adolescents. Loxapine powder for oral inhalation was administered via a single-use handheld drug device to children and adolescents (aged 10-17 years) with any condition warranting chronic antipsychotic use. Patients were dosed according to body weight and cohort (<50 kg [n = 15], 2.5 or 5 mg; ≥50 kg [n = 15], 5 or 10 mg); the first 6 patients (cohort 1) enrolled in each weight group received the lower dose. Patients were enrolled in the higher-dose group (cohort 2) after an interim pharmacokinetic and safety analysis of data from cohort 1. Blood samples were collected for 48 hours after dosing to determine the pharmacokinetic profile of loxapine and its metabolites. Safety was assessed using adverse event (AE), laboratory value, physical/neurologic examination, vital sign, electrocardiogram, suicidality, and extrapyramidal symptom assessment. Thirty patients were enrolled and evaluable for pharmacokinetics. Loxapine plasma concentrations peaked by 2 to 5 minutes in most patients; systemic exposure increased with dose in both weight subgroups. Loxapine terminal elimination half-life was ∼13...Continue Reading

References

Jan 31, 2004·The Journal of Pharmacology and Experimental Therapeutics·Joshua D RabinowitzAlejandro Zaffaroni
Jan 2, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Jon McClellanUNKNOWN Work Group on Quality Issues
Nov 17, 2009·Journal of Clinical Pharmacology·Daniel A SpykerJames V Cassella
Nov 9, 2010·Pediatric Emergency Care·Andrea J AdimandoCarl R Baum
Jan 5, 2011·The British Journal of Psychiatry : the Journal of Mental Science·Michael D LesemJames V Cassella
Jul 20, 2012·Allergy and Asthma Proceedings·Tara F Carr, Anju T Peters
Aug 27, 2013·Journal of the American Academy of Child and Adolescent Psychiatry·Jon McClellanUNKNOWN American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI)
Mar 27, 2015·Journal of Clinical Pharmacology·Daniel A SpykerJames V Cassella
Apr 11, 2015·Annals of General Psychiatry·Dina PopovicEduard Vieta
Mar 15, 2016·The Western Journal of Emergency Medicine·Scott L Zeller, Leslie Citrome

❮ Previous
Next ❯

Citations

Mar 30, 2019·Expert Opinion on Drug Discovery·Nicolas Vandenbussche, Peter J Goadsby
Jul 14, 2020·Expert Opinion on Drug Safety·Laura OrsoliniUmberto Volpe
Aug 9, 2021·Molecular Neurobiology·Matej ĽuptákJana Hroudová
Nov 30, 2021·Current Psychiatry Reports·Mehak PahwaRif S El-Mallakh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here